Quantum BioPharma's Unbuzzd Trial Results Draw National Scrutiny in Men's Fitness Feature

Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders as well as alcohol misuse disorders, drew national consumer attention this week after its Unbuzzd alcohol recovery formulation was featured in a Men's Fitness article by Lakshan Weeraratne. The coverage examined clinical trial results for the product, which Quantum invented and licensed to Unbuzzd Wellness Inc. For Texas investors and life sciences observers, the article matters because it places a Texas-based communications platform's client in front of a mainstream fitness audience at a moment when alcohol recovery products are drawing heightened consumer and regulatory interest.

The Men's Fitness piece highlighted findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, 24 of whom completed both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. Those figures, while preliminary, point to a potential commercial pathway for a product aimed at the recovery market rather than at intoxication itself.

The article also emphasized the study's limitations, including its small sample size, company sponsorship and mixed results across broader measures of hangover severity and cognitive impairment. It noted that larger, independent clinical trials are needed to confirm the results and cautioned that increased alertness does not indicate sobriety or fitness to drive. That framing is significant for the industry: consumer-facing supplement and wellness products increasingly face skepticism from regulators and health professionals, and media coverage that pairs promising data with explicit caveats can shape how quickly such products gain mainstream acceptance.

Quantum's interest in the category extends beyond over-the-counter sales. The company retains ownership of 19.84% of Unbuzzd as of March 31, 2026, and its agreement includes royalty payments of 7% of sales from unbuzzd until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, leaving room for higher-value clinical applications if the science advances. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum is separately focused on its lead compound, Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.

The Men's Fitness placement reflects the reach of BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences and life sciences sectors. It operates as one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers wire solutions through InvestorWire and editorial syndication to 5,000+ outlets. The platform also offers press release enhancement and social media distribution alongside corporate communications solutions. For Texas, where biotech commercialization and investor communications increasingly intersect, the announcement illustrates how early-stage clinical data can travel from a sponsored trial to a national fitness readership, and why the results, and their caveats, will be watched closely as Quantum pursues larger validation.